申请人:F. Hoffmann-La Roche AG
公开号:EP3760623A1
公开(公告)日:2021-01-06
Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:
and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
本文描述的是具有雌激素受体调节活性或功能的四氢吡啶并[3,4-b]吲哚-1-基化合物,其结构如式 I 所示:
及其立体异构体、同系物或药学上可接受的盐,并具有本文所述的取代基和结构特征。还描述了包括式 I 化合物的药物组合物和药物,以及单独或与其它治疗剂联合使用此类雌激素受体调节剂治疗介导或依赖于雌激素受体的疾病或病症的方法。